Although patients with cirrhosis are at high risk of HCC, there is variation in risk among individuals. We are collaborating with Dr. Hoshida at UT Southwestern to validate a novel blood-based signatures to help identify patients at highest risk for HCC development. The biomarker has shown promising results in several cohort studies, and we continue to evaluate its ability to enable tailored (precision) screening strategies.
Fujiwara N, Lopez C, Marsh T, Raman I, Marquez C, Paul S, Mishra S, Kubota N, Katz C, Kanzaki H, Gonzalez M, Quirk L, Deodhar S, Selvakumar P, Raj P, Parikh ND, Roberts L, Schwartz M, Nguyen M, Bfeler A, Page-Lester S, Srivastava S, Rinaudo J, Feng Z, Reddy R, Khaderi S, Asrani S, Kanwal F, El-Serag H, Marrero JA, Singal AG*, Hoshida Y*. Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in patients with cirrhosis. Gastroenterology 2025; 168(3): 556-567e.7
Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Maarouf Hoteit, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JF, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie J, Murphy CC*, Parikh ND* Direct Acting Antiviral Therapy is not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology 2019; 156(6): 1683-92.